News & Events

Financial Strategies Acquisition Corp., a Special Purpose Acquisition Company led by CEO Alexander V. Schinzing, today announced the execution of a definitive business combination agreement with Austin Biosciences Corp. (“Austin Biosciences”).

Austin Biosciences has developed a proprietary technology, Lipid-Albumin Stabilized Solid Nanoparticles (LASSN™), that leverages nanotechnology to improve the delivery of drugs.

Upon closing of the transaction, Austin Biosciences will become a wholly-owned subsidiary of the Company. Mr. Schinzing will serve as Chairman and Mr. Dr. Ram Bürgi-Krishnamurthy will serve as Chief Executive Officer of Austin Biosciences. The Company’s common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “ASTN.”